- Home
- LU vs IMVT Comparison
LU vs IMVT Comparison
Compare LU & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LU
- IMVT
- Stock Information
- Founded
- LU 2005
- IMVT 2018
- Country
- LU China
- IMVT United States
- Employees
- LU N/A
- IMVT N/A
- Industry
- LU Finance: Consumer Services
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LU Finance
- IMVT Health Care
- Exchange
- LU Nasdaq
- IMVT Nasdaq
- Market Cap
- LU 2.8B
- IMVT 2.7B
- IPO Year
- LU 2020
- IMVT N/A
- Fundamental
- Price
- LU $2.83
- IMVT $23.74
- Analyst Decision
- LU
- IMVT Buy
- Analyst Count
- LU 0
- IMVT 9
- Target Price
- LU N/A
- IMVT $27.71
- AVG Volume (30 Days)
- LU 3.0M
- IMVT 2.0M
- Earning Date
- LU 10-21-2025
- IMVT 11-10-2025
- Dividend Yield
- LU N/A
- IMVT N/A
- EPS Growth
- LU N/A
- IMVT N/A
- EPS
- LU N/A
- IMVT N/A
- Revenue
- LU $4,671,260,668.00
- IMVT N/A
- Revenue This Year
- LU N/A
- IMVT N/A
- Revenue Next Year
- LU N/A
- IMVT N/A
- P/E Ratio
- LU N/A
- IMVT N/A
- Revenue Growth
- LU N/A
- IMVT N/A
- 52 Week Low
- LU $2.22
- IMVT $12.72
- 52 Week High
- LU $4.57
- IMVT $32.10
- Technical
- Relative Strength Index (RSI)
- LU 37.27
- IMVT 70.64
- Support Level
- LU $2.81
- IMVT $23.31
- Resistance Level
- LU $2.92
- IMVT $26.17
- Average True Range (ATR)
- LU 0.17
- IMVT 1.28
- MACD
- LU -0.05
- IMVT 0.32
- Stochastic Oscillator
- LU 9.56
- IMVT 71.38
About LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is a technology-empowered personal financial services platform in China. The company address the large unmet demand for personal lending among small business owners as well as salaried workers in China and provides tailor-made wealth management solutions to China's middle class and affluent population. Its platform has two hubs namely Retail Credit Facilitation Hub and Wealth Management Hub.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.